Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
Scope of the Report:This is primarily attributed to the constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) which make individuals more susceptible to arrhythmia and heart failure. In addition, a number of factors such as the large number of technological advancements in CHF treatment devices, increased adoption rate of these devices, and rising emphasis on early intervention and primary prevention of heart-related disorders are responsible for driving the market. Conversely, stringent government regulations for the approval of CHF treatment devices, high cost of, and high preference to drugs for CHF treatment are some of the factors restraining the market growth.
The worldwide market for Congestive Heart Failure (CHF) Treatment Devices is expected to grow at a CAGR of roughly 5.7% over the next five years, will reach 15400 million US$ in 2023, from 11000 million US$ in 2017, according to a new study.
This report focuses on the Congestive Heart Failure (CHF) Treatment Devices in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers Abiomed, Inc.
Berlin Heart GmbH
Biotronik SE & Co. KG
Boston Scientific Corporation
HeartWare International, Inc.
Jarvik Heart, Inc.
LivaNova PLC
Medtronic
ReliantHeart Inc.
St. Jude Medical, Inc.
Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers Cardiac Resynchronization Therapy (CRT)
Implantable Cardioverter Defibrillators (ICDs)
Market Segment by Applications, can be divided into Left Ventricular Assist Device (LVAD)
Right Ventricular Assist Device (RVAD)
Biventricular Assist Device (BIVAD)
There are 15 Chapters to deeply display the global Congestive Heart Failure (CHF) Treatment Devices market.
Chapter 1, to describe Congestive Heart Failure (CHF) Treatment Devices Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Congestive Heart Failure (CHF) Treatment Devices, with sales, revenue, and price of Congestive Heart Failure (CHF) Treatment Devices, in 2018 and 2019;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2018 and 2019;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Congestive Heart Failure (CHF) Treatment Devices, for each region, from 2015 to 2020;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2015 to 2020;
Chapter 12, Congestive Heart Failure (CHF) Treatment Devices market forecast, by regions, type and application, with sales and revenue, from 2020 to 2026;
Chapter 13, 14 and 15, to describe Congestive Heart Failure (CHF) Treatment Devices sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
